Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.51 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.49 |
| ▸ | CASP2 | P42575 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 6/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20113585 | 0.86 | FAAH (0.55) | FAAHDNM1EPHX2TSHR | |
| SCHEMBL2011680 | 0.84 | FAAH (0.52) | FAAHEPHX2TSHR | |
| SCHEMBL18115162 | 0.83 | FAAH (0.44) | FAAHACHEEPHX2CNR1CNR2 | |
| SCHEMBL20104903 | 0.82 | HPGD (0.49) | FAAHCNR1CNR2TSHR | |
| SCHEMBL9500025 | 0.81 | TSHR (0.39) | FAAHACHECNR1CNR2TSHR | |
| SCHEMBL9497917 | 0.81 | DNM1 (0.56) | FAAHDNM1TSHR | |
| SCHEMBL18752940 | 0.80 | RECQL (0.57) | FAAHEPHX2CNR1CNR2TSHR | |
| SCHEMBL18753010 | 0.79 | PTPN1 (0.41) | FAAHEPHX2CNR1CNR2TSHR | |
| SCHEMBL2014567 | 0.79 | FAAH (0.48) | FAAHEPHX2TSHR | |
| SCHEMBL20975838 | 0.79 | KMT2A (0.47) | FAAHACHETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118676-A1 | NITRIC OXIDE DONATING DERIVATIVES OF LATANOPROST FREE ACID | NICOX S.A. (FR) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118676-A1 | NITRIC OXIDE DONATING DERIVATIVES OF LATANOPROST FREE ACID | PTGIS, NOS2, NOS1 | FAAH 233/4885DNM1 1393/4885CASP2 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.